Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
61 lessons
9mResearchAdvanced
GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition
GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
8mResearchAdvanced
GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026
GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.
8mResearchAdvanced
Retatrutide and Visceral Fat: Why the Scale Misses the Real Signal
Scale weight is noisy. If you are using retatrutide, waist trend, body composition, protein intake, and strength matter more than a single weigh-in.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mPeptidesIntermediate
GLP-1s, Delayed Gastric Emptying, and Surgery: What the Perioperative Debate Means
GLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.
9mPeptidesIntermediate
Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means
Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
8mResearchAdvanced
BPC-157 and GLP-1 Side Effects: What the Research Really Shows
GLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
7mPeptidesIntermediate
Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means
Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
7mProtocolsIntermediate
GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping
A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.
7mResearchAdvanced
GLP-1 Lean Mass Loss: What 2026 Data Shows
A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
8mResearchAdvanced
Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch
Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mResearchAdvanced
GLP-1 Nutrition Strategy: Protein, Muscle, and Labs
New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
9mResearchAdvanced
Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide
The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps
Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
7mStart hereBeginner
Peptides for Women: What to Know Before You Start
Women have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
8mProtocolsIntermediate
Retatrutide Not Working for Weight Loss? Here's What to Check
You've been on Retatrutide for 4-6 weeks and the scale hasn't budged. Before you give up or double your dose, here are the real reasons Reta might not be 'working' — and what to actually do about it.
8mProtocolsIntermediate
MOTS-C After Stopping GLP-1 Agonists: Dosing and Protocol Guide
Finished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.
9mProtocolsIntermediate
Stacking Tesamorelin and MOTS-C with Retatrutide: A Complete Protocol Guide
Already on Reta and ready to add compounds? Here's how to stack Tesamorelin and MOTS-C with Retatrutide for maximum fat loss and recomp.
9mProtocolsIntermediate
Switching from Tirzepatide to Retatrutide: The Complete Transition Guide
Already on tirzepatide and considering retatrutide? Here's exactly how to make the switch—starting doses based on your current Tirz level, what the glucagon component changes, and how to avoid common transition mistakes.
7mPeptidesIntermediate
Why Peptide Therapy Is Going Mainstream in 2026
Peptide therapy searches on TikTok jumped 459% in early 2026. Here's what's driving the explosion, which peptides are trending, and what you need to know before you start.
9mProtocolsIntermediate
Retatrutide Dosing for Beginners: Your First 12-Week Titration Schedule
Retatrutide is one of the most powerful GLP-1/GIP/glucagon receptor agonists available. But starting at the wrong dose — or jumping up too fast — is the #1 beginner mistake. Here's the complete titration roadmap.
9mPolicyAdvanced
Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community
For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
9mProtocolsIntermediate
The Complete GLP-1 + Mitochondrial Fat Loss Stack: Reta, MOTS-C, SS-31, AOD, and SLU-PP-332
Running Retatrutide and wondering what to add? This guide breaks down how MOTS-C, SS-31, AOD-9604, and SLU-PP-332 layer onto a GLP-1 protocol — and why they're not redundant.
10mProtocolsIntermediate
5-Amino-1MQ: The NNMT Inhibitor That Stacks With GLP-1s and MOTS-C
Most fat-loss compounds either suppress appetite or boost energy expenditure. 5-Amino-1MQ does something different — it blocks the enzyme that burns through your NAD+ and keeps fat cells from ever getting broken down. Here's why it stacks so well with Reta and MOTS-C.
9mPeptidesIntermediate
Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss
Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.
9mResearchAdvanced
Why Your Weight Isn't Moving on Retatrutide (And What to Do About It)
Hitting a plateau on Retatrutide is common and usually temporary. Here's the science behind GLP-1 stalls and the practical steps to break through them.
8mProtocolsIntermediate
AOD-9604: The HGH Fragment That Targets Fat Without the Side Effects
AOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.
8mPeptidesIntermediate
BRP Peptide: Stanford's AI-Discovered 'Natural Ozempic' Explained
A Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
11mPeptidesIntermediate
Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1
A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.
10mProtocolsIntermediate
Peptide Stacking for Muscle Preservation on GLP-1s: The Complete Protocol
The biggest risk with GLP-1 weight loss drugs isn't the fat loss — it's the muscle you lose with it. Strategic peptide stacking can tip the balance toward true body recomposition.
9mProtocolsIntermediate
Retatrutide: How to Reconstitute and Take Your First Dose
Everything you need to know before your first retatrutide injection — reconstitution math, dose calculations, injection technique, and what to expect if you have prior GLP-1 sensitivity.
9mResearchAdvanced
Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed
Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
10mPeptidesIntermediate
The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work
Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.
10mPeptidesIntermediate
Latest Peptide Research Breakthroughs: What's Coming in 2026
The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.
10mPeptidesIntermediate
How Retatrutide Works: The Science Behind the Triple-Receptor Agonist
Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.
8mStart hereBeginner
Retatrutide Beginner's Guide: Reconstitution, Dosing & Getting Started
New to retatrutide? This guide covers everything: how much BAC water to add, dose calculations for common vial sizes, starting doses, and titration schedules for safe, effective results.
10mPeptidesIntermediate
Why Retatrutide Preserves Muscle Better Than Tirzepatide
Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mPeptidesIntermediate
Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial
Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mPeptidesIntermediate
Retatrutide: The Triple-Action Weight Loss Peptide Explained
Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
10mPeptidesIntermediate
Peptide Research Breakthroughs in 2026: What Clinical Trials Show
2026 marks a pivotal year for peptide research. Here's what the latest clinical data reveals about the most promising peptide candidates and their real-world applications.
12mPeptidesIntermediate
GLP-1 Agonists for Metabolic Health: Clinical Evidence & Body Recomposition Strategy
GLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.
9mResearchAdvanced
Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows
Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
18mPeptidesAdvanced
The Ultimate Peptide Tier List for 2026: S-Tier to F-Tier Ranked
From BPC-157 and GLP-1 agonists at the top to overhyped flops at the bottom — here's every major peptide ranked for 2026 across fat loss, skin, longevity, and recovery.
11mPeptidesIntermediate
Semaglutide for Weight Loss: Complete Guide to GLP-1 Peptide Therapy
Explore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
10mPeptidesIntermediate
Tirzepatide: The Dual Agonist Revolution in Weight Loss
Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.
Also available at /blog for legacy links.